4

PRIMARY DOCUMENT

Company: ALNYLAM PHARMACEUTICALS, INC.
Filed: May 19, 2023
Period of Report: May 18, 2023
Accession Number: 0001735276-23-000059

View Document ↗ View on SEC.gov ↗